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A B S T R A C T
Objective: To evaluate the diagnostic performance of the Inbios (Seattle, US) and Euroimmun (Luebeck,
Germany) chikungunya virus (CHIKV) IgM enzyme-linked immunoassays (ELISAs).
Methods: We evaluated the tests’ accuracy on sera from 372 patients enrolled in an acute febrile illness
surveillance study performed in Salvador, Brazil from Sept/2014 to Jul/2016, a period of simultaneous
CHIKV, dengue (DENV), and Zika (ZIKV) virus transmission. We assessed the sensitivity on acute and
paired convalescent sera from RT-PCR-confirmed CHIKV cases (collected at median one and 19 days post-
onset of symptoms, respectively), and the specificity on sera of RT-PCR-confirmed DENV and ZIKV cases,
and on negative patients.
Results: The Inbios and Euroimmun tests’ sensitivities for acute samples were 4.0% and 10.3%, while for
convalescent samples they were 92.4% and 96.9%, respectively. Overall, Inbios IgM ELISA specificities for
acute and convalescent samples were 97.7% and 90.5%, respectively, and Euroimmun specificities were
88.5% and 83.9%, respectively.
Conclusions: Both tests presented high sensitivity for convalescent samples. However, the Euroimmun
test returned more equivocal results and presented a slightly lower specificity, which might result in a
higher rate of false positives if the test is used in scenarios of low CHIKV transmission, when the chance of
CHIKV infection is lower.
© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Chikungunya virus (CHIKV) is an alphavirus transmitted by
Aedes (Stegomyia) spp. mosquitoes (WHO 2008). Transmission was
initially restricted to small outbreaks and sporadic cases in Africa
and Asia, but since early 2000s the virus has caused large
outbreaks in India and Southeast Asia. In 2013, CHIKV spread for
the first time in the modern scientific era to the Americas,
including throughout the Caribbean (Zeller et al., 2016) and Latin* Corresponding author at: Instituto Gonçalo Moniz, Fundação Oswaldo Cruz. Rua
Waldemar Falcão, 121, Candeal, Salvador, BA, 40296-710, Brazil.
E-mail address: guilherme.ribeiro@bahia.fiocruz.br (G.S. Ribeiro).
https://doi.org/10.1016/j.ijid.2019.11.001
1201-9712/© 2019 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).America (Yactayo et al., 2016). In 2016 alone,~350,000 cases were
reported in in Latin America (PAHO 2017), the majority (>260,000)
occurring in Brazil, particularly in the northeast (BRASIL 2017).
Acute clinical manifestations associated with CHIKV infections
are non-specific, usually including fever, rash, and arthralgia, the
latter being the most prominent symptom that may last for months
or years, causing chronic disabilities (WHO 2008). In areas where
other arboviruses with similar clinical manifestations co-circulate,
such as dengue (DENV) and Zika (ZIKV) viruses, laboratory
diagnostic tools that distinguish CHIKV infections from them, as
well as from other acute febrile illness, are essential for effective
surveillance and appropriate clinical management.
Here, we evaluated the diagnostic performance of two
commercially available enzyme-linked immunoassays (ELISAs)ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Germany) for detection of CHIKV-specific IgM antibodies in acute
and convalescent paired sera of febrile outpatients from Salvador,
Brazil, during a period of simultaneous CHIKV, DENV, and
ZIKV transmission (Cardoso et al., 2015, 2017; Silva et al., 2019).
The tests’ accuracies were estimated using results of reverse-
transcription polymerase chain reaction (RT-PCR) as the gold-
standard reference test.
Methods
Surveillance for acute febrile illness
From September 2014 to July 2016, we enrolled patients
attending a public emergency health unit of Salvador (São Marcos
Emergency Center, SMEC) in an acute febrile illness (AFI) enhanced
surveillance study (Silva et al. 2019). Inclusion criteria were 6
months of age and reported or measured fever (37.8 C) up to 7
days of duration. Demographic and clinical characteristics data of
patients who consented to participate were obtained through a
structured standardized interview. In addition, acute-phase
(at enrollment) and paired convalescent-phase (15 days after
enrollment) blood samples were drawn for arboviral diagnosis.
Samples were refrigerated until centrifugation, and obtained sera
were stored at 20 C and 70 C for serological and molecular
testing, respectively.
RT-PCR testing for arboviral diagnosis
All acute-phase sera, which had not been previously thawed,
were submitted to RNA extraction and tested by RT-PCR for DENV,
ZIKV, and CHIKV. Briefly, viral RNA was extracted using the
Maxwell1 16 Total RNA Purification kit (Promega, Wisconsin, USA)
or QIAmp1 Viral RNA mini kit commercial kit (Qiagen, Hilden,
Germany) according to manufacturer’s specifications. Subsequent-
ly, RT-PCR (Access RT-PCR kit- Promega, Wisconsin, USA) was
performed separately on the extraction product using specific
primers to identify DENV (Lanciotti et al., 1992), ZIKV (Balm et al.,
2012) or CHIKV (Edwards et al., 2007). For the IgM ELISA
evaluation, we defined confirmed CHIKV, DENV, and ZIKV cases
based on a positive result in each arboviral-specific RT-PCR. We
defined as non-arboviral AFI patients those presenting negative
RT-PCR for all the three tested arboviruses.
Detection of CHIKV-specific IgM antibodies by ELISA
We tested the acute- and paired convalescent-phase sera
available from all the CHIKV, DENV, and ZIKV RT-PCR-positive
patients enrolled during surveillance with both the CHIKjj Detect
IgM-capture ELISA kit (cat no. CHKM-R, Inbios International, Inc.,
Seattle, USA) and the Anti-Chikungunya virus ELISA (IgM) Test (cat
no. EI 293a-9601 M, Euroimmun, Luebeck, Germany). We also
applied the Inbios and the Euroimmun CHIKV IgM ELISA tests to
the acute- and paired convalescent-phase sera from 175 patients
randomly selected from those with negative RT-PCR results (for all
3 arboviruses) and with paired sera available. This random sample
of 175 RT-PCR negative patients provided good precision for the
specificity estimation (95% confidence for a precision of 4% and
an anticipated specificity 90%).
Tests were performed according to the manufacturer’s instruc-
tions. The ELISA reading was performed by automated microplate
reader at 450 nm (TECAN, Maennedorf, Switzerland). The optical
density ratio obtained from the patients’ serum and the calibrator
was interpreted according to the manufacturer. Samples yielding
equivocal/borderline ratio results were repeated once, and the
second results were considered final.Detection of CHIKV-specific IgG antibodies by ELISA
In order to further investigate whether individuals from the
control groups (DENV, ZIKV, and negative patients) presenting IgM
positive results by either tests truly represented false positive cases
or actually represented individuals who had past CHIKV infections
and retained a positive CHIKV IgM response, we used the CHIKjj
DetectTM IgG ELISA Kit (cat no. CHKG-C, Inbios International, Inc.,
Seattle, USA) to test all available acute-phase samples from control
patients who had a IgM positive result in either Inbios or
Euroimmun IgM-ELISA in the acute- and/or convalescent-phase
sera. We also applied the same CHIKV IgG test on the acute- and
convalescent-phase sera of CHIKV RT-PCR positive cases that
yielded a negative IgM result in the convalescent-phase sample to
investigate possible false positive results in the RT-PCR.
Data analysis
Patients included in the study were described according to their
demographic and clinical characteristics. The Wilcoxon–Mann–
Whitney test or the Fisher’s exact test was used to compare these
characteristics between the patients with positive and negative RT-
PCR result for CHIKV. Accuracy measures were calculated for both
acute- and convalescent-phase samples using the CHIKV RT-PCR
result as the reference test. In addition to the overall specificity of
the ELISAs, we also calculated specificities by subgroups, according
to the RT-PCR result for the other tested arboviruses: i) DENV-
positive cases; ii) ZIKV-positive cases; and iii) negative for the
three tested arboviruses. Confidence intervals of 95% (95% CI) were
calculated for all accuracy measurements.
Ethics statement
The Research Ethics Committee at Instituto Gonçalo Moniz,
Fundação Oswaldo Cruz approved this study. All adult subjects
provided written informed consent and participants <18 years of
age who were able to read provided written assent following
written consent from their parent or guardian. All study data were
anonymized before analysis.
Results
The surveillance study enrolled 948 AFI patients with at least
one available sample for laboratory testing. However, due to
insufficient volumes of sera, RT-PCR for DENV and CHIKV was
performed for 915 patients (96.5%), while RT-PCR for ZIKV was
performed for 914 patients (96.4%). Among the patients who
underwent RT-PCR testing, 197 (21.5%) were positive for at least
one of the arboviruses and the remaining 718 (78.5%) were
negative for all three arboviruses. Specifically, mono-infections
were detected for 184 (20.1%) cases: 139 (15.2%) of CHIKV, 32 (3.5%)
of DENV, and 13 (1.4%) of ZIKV, whereas co-infections occurred for
13 (1.4%) cases: 12 (1.3%) CHIKV/DENV co-infections, and one
(0.1%) DENV/ZIKV co-infection.
The 13 CHIKV/DENV co-infection cases were included among
the RT-PCR-confirmed chikungunya cases during the sensitivity
analyses, but not among the DENV cases during the specificity
analyses. The DENV/ZIKV co-infection case was included among
both the DENV and the ZIKV cases for the specificity analyses. Thus,
based on the RT-PCR results, the final number of CHIKV-RT-PCR-
confirmed cases used for the sensitivity analyses was 151 cases
(139 CHIKV mono-infections plus 12 CHIKV co-infections with
DENV). The final number of non-CHIKV cases used for the
specificity analyses was 221 cases (32 DENV, 13 ZIKV, 1 DENV/
ZIKV co-infection, and 175 randomly selected among the 718 AFI
cases without RT-PCR evidence for an arboviral infection).
Table 1
Demographics, clinical characteristics, and serum sample availability for 372 acute febrile illness (AFI) patients included in the CHIKV IgM ELISA evaluation study, and
according to RT-PCR result, Salvador, September 2014 to July 2016.
Characteristics AFI patients according to RT-PCR result for
CHIKV








Neg. for the three
arboviruses (n = 175)
Number with the finding/total with available data (%)
Demographic
Agec 34 (22 – 45)d 28 (19–40)d 31 (15–40) 22.5 (15–41) 28 (20–40)
Males 81/151 (53.6) 98/220 (44.6) 16/33 (48.5) 6/14 (42.9) 76/174 (43.7)
Clinical Manifestations
Myalgia 144/151 (95.4)d 184/218 (84.4)d 26/32 (81.3) 12/14 (85.7) 147/173 (85.0)
Arthralgia 143/151 (94.7)d 148/221 (67.0)d 21/33 (63.6) 8/14 (57.1) 120/175 (68.6)
Polyarthralgia 136/143 (95.1) 145/148 (98.0) 21/21 (100) 8/8 (100) 117/120 (97.5)
Symmetric 128/143 (89.5) 142/145 (97.9) 21/21 (100) 8/8 (100) 114/117 (97.4)
Headache 141/151 (93.4) 203/219 (92.7) 30/32 (93.8) 13/14 (92.9) 161/174 (92.5)
Retro-orbital pain 107/150 (71.3) 155/218 (71.1) 22/32 (68.8) 10/14 (71.4) 124/173 (71.7)
Swollen joints 63/151 (41.7)d 53/221 (24.0)d 12/33 (36.4) 5/14 (35.7) 37/175 (21.1)
Vomit 35/151 (23.2) 59/221 (26.7) 10/33 (30.3) 2/14 (14.3) 48/175 (27.4)
Rash 38/150 (25.3) 75/221 (33.9) 14/33 (42.4) 10/14 (71.4) 52/175 (29.7)
Pruritus 25/151 (16.6)d 71/221 (32.1)d 12/33 (36.4) 10/14 (71.4) 50/175 (28.6)
Blood sample collection
Acute-phase sample 151/151 (100) 221/221 (100) 33/33 (100) 14/14 (100) 175/175 (100.0)
Time (days) between symptoms onset and
sample collection c
1 (1–2)d 3 (2–4)d 4 (3–6) 2.5 (2–4) 3 (1–4)
Convalescent-phase sample 67/151 (44.4)d 200/221 (90.5)d 18/33 (54.6) 8/14 (57.1) 175/175 (100.0)
Time (days) between symptoms onset and
sample collectionc
19 (14–33) 24 (16–38) 21 (16–42) 27 (18.5–43.5) 23.5 (16–38)
Abbreviations: AFI = acute febrile illness; RT-PCR = reverse transcription polymerase chain reaction; CHIKV = chikungunya virus; DENV = dengue virus; ZIKV = Zika virus;
Pos. = positive; Neg. = Negative.
a Of the 151 CHIKV positive patients, 139 had a CHIKV mono-infection and 12 had a CHIKV and DENV co-infection. These 12 CHIKV and DENV co-infected patients were only
included in the group of CHIKV positive patients (and not in the group of DENV positive patients).
b One patient was simultaneously positive for DENV and ZIKV and was included in both groups.
c Median (interquartile range).
d P-value < 0.05 by Wilcoxon–Mann–Whitney or Fisher exact for comparisons between CHIKV positive and CHIKV negative patients.
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(94.7%) compared to non-CHIKV cases (67.0%) (p < 0.001), as were
myalgia (95.4% vs 84.4%, p = 0.001), and swollen joints (41.7% vs
24.0%, p < 0.001) (Table 1). However, rash (25.3% vs 33.9%, p = 0.08)
and pruritus (16.6% vs 32.1%, p = 0.001) were less frequent among
CHIKV cases than non-CHIKV cases. CHIKV cases also sought
medical assistance earlier, and thus had their acute-phase blood
sample collected sooner than the non-CHIKV patients (median
of one vs. three days post-onset of symptoms, respectively)
(p < 0.001).
Of the 635 samples undergoing the Inbios IgM ELISA testing
(369 acute- and 266 convalescent-phase samples), 8 (1.3%)
presented equivocal results (three CHIKV-RT-PCR-positive acute-
phase samples, four CHIKV RT-PCR negative acute-phase samples,
and one CHIKV RT-PCR positive convalescent-phase sample), and
when retested produced a valid result. Of the 621 samples tested by
the Euroimmun IgM ELISA (360 acute-phase and 261 convalescent-
phase samples), 36 (5.8%) presented equivocal results (8 CHIKV RT-
PCR positive acute-phase samples, 14 CHIKV RT-PCR negative
acute-phase samples, three CHIKV-RT-PCR-positive convalescent-
phase samples, and 11 CHIKV-RT-PCR-negative convalescent-
phase samples). After retesting, an equivocal result remained for
9 (1.4%) of them (one CHIKV RT-PCR positive acute-phase sample,
five CHIKV RT-PCR negative acute-phase sample, one CHIKV RT-
PCR positive convalescent-phase sample, and two CHIKV-RT-PCR-
negative convalescent-phase samples).
For acute-phase sera, the Inbios IgM-ELISA sensitivity was 4.0%
(3.7% for samples obtained 3 days post-symptoms onset (DPSO)
and 7.1% for samples obtained 4–7 DPSO) (Table 2). For
convalescent-phase sera, the Inbios IgM-ELISA sensitivity was
92.4%. Considering a positive IgM-ELISA result in either the acute-
or convalescent-phase sample, of the 66 patients with available
paired samples, the combined Inbios test sensitivity was 92.4%.Considering a positive IgM-ELISA result only in the convalescent-
phase samples for the 64 RT-PCR-CHIKV-confirmed patients who
had a negative result in the Inbios IgM-ELISA applied to the acute-
phase sample, we observed a seroconversion sensitivity of 92.2%.
Sensitivity of the Euroimmun IgM-ELISA was 10.3% for acute-phase
samples (9.2% and 21.4% for samples obtained within 3 and 4–7
DPSO, respectively), 96.9% for convalescent-phase samples, 96.9%
for combined acute- and convalescent-phase samples, and 96.7%
when assessing seroconversions (Table 2).
To ascertain potential reasons for occurrence of false negative
results in the CHIKV IgM ELISA tests performed on the
convalescent-phase samples of RT-PCR-confirmed CHIKV cases,
we evaluated the CHIKV IgG status of the five cases whose
convalescent-phase sera were IgM negative by either ELISA tests.
We found that three cases presented IgG seroconversion, one was
IgG-positive in both the acute- and convalescent-phase sera, and
one was negative for both acute- and convalescent-phase sera.
Overall, considering all AFI patients with a negative CHIKV RT-
PCR result, specificity for the Inbios IgM-ELISA was above 90% in
both acute- (97.7%) and convalescent-phase samples (90.5%),
whereas the specificity for the Euroimmun IgM-ELISA was 88.6% in
acute- and 83.9% in convalescent-phase samples (Table 3). Among
DENV cases, the Inbios and Euroimmun IgM-ELISA specificities
were 83.9% and 82.8% for the acute-phase samples, and 88.9% and
83.3% for the convalescent-phase samples, respectively. Among
ZIKV cases, specificities of the Inbios and Euroimmun IgM-ELISA
were 92.9% and 83.3% for the acute-phase samples, and 87.5% and
87.5% for the convalescent-phase samples. In the RT-PCR-negative
control group, the Inbios and Euroimmun specificities were 100.0%
and 89.5% for acute-phase samples, and 90.3% and 83.3% for
convalescent-phase samples, respectively.
To investigate whether maintenance of CHIKV IgM antibodies
after a prior CHIKV infection could explain a positive IgM ELISA
Table 2
Sensitivity of the Inbios and Euroimmun chikungunya virus IgM-ELISAs in the acute- and convalescent-phase sera, and according to seroconversions.













In acute samplea 6 150 4.0% (1.5–8.5) 15 145 10.3% (5.9–16.5)
3 DPOS 5 136 3.7% (1.2–8.4) 12 131 9.2% (4.8–15.5)
0–1 DPOS 1 80 1.3% (0.0–6.8) 4 78 5.1% (1.4–12.6)
2–3 DPOS 4 56 7.1% (2.0 – 17.3) 8 53 15.1% (6.8 –27.6)
4–7 DPOS 1 14 7.1% (0.2 – 33.9) 3 14 21.4% (4.7–50.8)
In convalescent sampleb 61 66 92.4% (83.2–97.5) 63 65 96.9% (89.3–99.6)
<30 DPOSc 44 46 95.7% (85.2–99.5) 44 46 95.7% (85.2–99.5)
14 DPOS 20 20 100.0% (83.2–100.0) 20 20 100.0% (83.2–100.0)
15-29 DPOS 24 26 92.3%(74.9–99.0) 24 26 92.3% (74.9–99.1)
30 DPOSd 17 20 85.0% (62.1–96.8) 19 19 100.0% (82.4–100.0)
Combined
Positivity in acute or in convalescent paired samplesb 61 66 92.4% (83.2–97.5) 63 65 96.9% (89.3–99.6)
Seroconversion between paired samplese 59 64 92.2% (82.7–97.4) 58 60 96.7% (88.5–99.6)
Abbreviations: CHIKV = chikungunya virus; RT-PCR = reverse transcription polymerase chain reaction; Pos. = positive; CI = confidence interval; DPOS = days post onset of
symptoms.
a Of the 151 CHIKV RT-PCR positive cases enrolled, acute sera samples were available for testing by the Inbios IgM-ELISA for 150 cases (138 mono-infected patients and 12
CHIKV and DENV co-infected patients), and for testing by the Euroimmun IgM-ELISA for 146 cases (138 mono-infected patients and 8 CHIKV and DENV co-infected patients),
of which one mono-infected yielded an equivocal result and was excluded from the analysis.
b Of the 67 CHIKV RT-PCR positive cases enrolled for whom a convalescent sera was collected, convalescent sera samples were available for testing by the Inbios IgM-ELISA
for 66 cases (64 mono-infected patients and 2 CHIKV and DENV co-infected patients), and for testing by the Euroimmun IgM-ELISA for 66 cases (64 mono-infected patients
and 2 CHIKV and DENV co-infected patients), of which one mono-infected yielded an equivocal result and was excluded from the analysis.
c Minimum of 9 days post onset of symptoms.
d Maximum of 70 days post onset of symptoms.
e Seroconversion was evaluated only for the RT-PCR-positive CHIKV patients with available paired sample whose acute-phase sample was negative on the IgM-ELISA.
Table 3
Specificity of the Inbios and Euroimmun chikungunya virus IgM-ELISAs in the acute- and convalescent-phase sera, and according to other arboviral diagnosis.














Non-CHIKV AFI patients 214 219 97.7% (94.8–99.3) 185 209 88.5% (83.4–
92.5)
DENV cases 26 31 83.9% (66.3–94.6) 24 29 82.8% (64.2–
94.2)
ZIKV cases 13 14 92.9% (66.1–99.8) 10 12 83.3% (51.6–
97.9)
AFI patients negative for the 3
arboviruses
175 175 100.0% (97.9–
100.0)
153 171 89.5% (83.9–
93.6)
In convalescent sampleb
Non-CHIKV AFI patients 181 200 90.5% (85.6–94.2) 162 193 83.9% (78.0–
88.8)
DENV cases 16 18 88.9% (65.3–98.6) 15 18 83.3% (58.6–
96.4)
ZIKV cases 7 8 87.5% (43.4–99.7) 7 8 87.5% (47.4–
99.7)
AFI patients negative for the 3
arboviruses
158 175 90.3% (84.9–94.2) 140 168 83.3% (76.8–
88.6)
Abreviations: CHIKV = chikungunya virus; RT-PCR = reverse transcription polymerase chain reaction; Neg. = negative; CI = confidence interval; AFI = acute febrile illness;
DENV = dengue virus; ZIKV = Zika virus.
a Of the 221 CHIKV RT-PCR negative cases included in this evaluation study, acute-phase serum samples were available for testing by the Inbios IgM-ELISA for 219 cases,
including 30 patients with a DENV mono-infection, 13 patients with a ZIKV mono-infection, 1 patient with a DENV and ZIKV co-infection (included in both DENV and ZIKV
groups), and 175 patients with negative RT-PCR results for CHIKV, DENV, and ZIKV. Acute-phase sera were available for testing by the Euroimmun IgM-ELISA for 214 cases,
including 28 patients with a DENV mono-infection, 11 patients with a ZIKV mono-infection, 1 patient with a DENV and ZIKV co-infection (included in both DENV and ZIKV
groups), and 174 patients with negative RT-PCR results for CHIKV, DENV, and ZIKV (5 of which yielded an equivocal result and were excluded from the analysis).
b Of the 221 CHIKV RT-PCR-negative cases included in this evaluation study, convalescent-phase samples were available for testing by the Inbios IgM-ELISA for 200 cases,
including 17 patients with a DENV mono-infection, 7 patients with a ZIKV mono-infection, 1 patient with a DENV and ZIKV co-infection (included in both DENV and ZIKV
groups), and 175 patients with negative RT-PCR results for CHIKV, DENV, and ZIKV. Convalescent-phase serum samples were available for testing by the Euroimmun IgM-
ELISA for 195 cases, including 17 patients with a DENV mono-infection, 7 patients with a ZIKV mono-infection, 1 patient with a DENV and ZIKV co-infection, and 170 patients
with negative RT-PCR results for CHIKV, DENV, and ZIKV (2 of which yielded an equivocal result and were excluded from the analysis).
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the presence of CHIKV IgG in the acute-phase sera of the 44 CHIKV
RT-PCR negative cases that had a positive IgM ELISA result in the
acute- or convalescent-phase sample by either test. We found that
39 (88.6%) cases had negative results for the CHIKV IgG in the
acute-phase sera, and thus did not have a prior CHIKV infection,
while five (11.4%) cases had CHIKV IgG in their acute-phase sample.Of these five cases with evidence of a prior CHIKV infection, the
Inbios test returned a positive IgM result for three cases (one in
both the acute- and convalescent-phase sera and two in the acute-
phase sera of cases that did not have paired sample). Excluding
these three cases from the Inbios test evaluation, the overall Inbios
specificities did not substantially differ (99.1% (214/216) for acute-
phase sera and 91.0% (181/199) for convalescent-phase sera).
42 M. Kikuti et al. / International Journal of Infectious Diseases 91 (2020) 38–43All five cases with evidence of a prior CHIKV infection were IgM-
positive by the Euroimmun test (two in both the acute- and
convalescent-phase sera, one only in the acute-phase sample with
a negative result in the convalescent-phase serum, and two in the
acute-phase samples of cases that did not have a paired sample).
Excluding these 5 cases from the test evaluation, the overall
Euroimmun specificities also did not substantially differ (90.7%
(185/204) and 84.7% (161/190) for acute- and convalescent-phase
sera, respectively).
Discussion
Our evaluation of the Inbios and the Euroimmun IgM ELISAs
shows that, despite low sensitivities when applied to sera obtained
within the first week of chikungunya symptoms onset, they
performed well when convalescent-phase samples were used
(sensitivity >92%). Overall, specificities were also high for Inbios
(91–98%) and slightly lower for Euroimmun (84–89%).
The low sensitivity for both tests on acute-phase samples was
expected, because all the confirmed chikungunya cases included in
this evaluation were detected by RT-PCR and, thus, were still in the
viremic phase of the illness, when IgM antibody presence is
unlikely. Although the Euroimmun IgM-ELISA presented a higher
sensitivity for acute-phase samples than the Inbios test (10% vs. 4%,
respectively), it was still sub-optimal, reaching a maximum of
21.4% for samples obtained 4–7 days after symptom onset.
Despite the good specificities, positive IgM ELISA results for
both tests occurred in 10–15% of the samples of CHIKV RT-PCR-
negative cases, which can be explained in two ways. First, the
reference diagnostic test (the CHIKV RT-PCR) may have failed to
confirm CHIKV infections in some of the study patients presenting
low viremia; thus, it is possible that a fraction of the positive IgM
ELISA results among CHIKV RT-PCR-negative patients actually
represent true acute infections. Second, as Salvador experienced an
outbreak of CHIKV during 2015 (Cardoso et al., 2015, 2017; Silva
et al., 2019), it is also possible that some of the CHIKV-RT-PCR-
negative patients included in our study experienced a recent
CHIKV infection (1–3 months before study enrollment), and that
CHIKV IgM antibodies persisted during our study. In that regard,
our IgG detection analysis showed that prior CHIKV infection could
only explain a small fraction of the false positive IgM ELISA results.
However, in settings where CHIKV transmission is epidemic, a
positive IgM result may represent a recent, rather than an acute
infection. In such a context, efforts for early diagnosis by molecular
methods should be encouraged to ensure accurate CHIKV
detection. It is also important to highlight that cross-reactions
with DENV or ZIKV infections are unlikely, because CHIKV is an
alphavirus, while DENV and ZIKV are antigenically unrelated
flaviviruses.
Previous evaluations demonstrated 100% sensitivity and
93–100% specificity for the Inbios IgM-ELISA, and 94–100%
sensitivity and 96–100% specificity for the Euroimmun IgM-ELISA
in a panel of serum samples from laboratory-confirmed CHIKV
cases and a diverse set of controls (Johnson et al., 2016). Sensitivity
and specificity of the Euroimmun IgM-ELISA were also reported to
be 85% and 82%, respectively, in a panel of samples from reference
laboratories, with cross-reactivity reported with o’nyong-nyong
virus (Prat et al., 2014). Here, we evaluated the tests performance
in a panel of samples obtained from febrile outpatients recruited in
the context of intense arboviral co-circulation, reflecting a
challenging but realistic scenario of test use. However, we did
not include patients with other alphaviruses (such as Venezuelan
equine encephalitis, Madariaga, and Mayaro viruses) among the
control group, because there is no evidence of their transmission in
this region of the country. A few sporadic or outbreak-associated
human cases of these arboviral infections have occurred in otherparts (North and Central-West) of Brazil (Lopes et al., 2014; Vieira
et al., 2015) and further studies should be performed to determine
the specificity of CHIKV IgM ELISA tests in such settings where
different alphaviruses co-circulate.
In summary, our findings indicate an overall good sensitivity of
both tests for convalescent-phase serum samples. Conversely,
sensitivity in acute-phase samples was low for both tests, as
expected. These results reinforce the notion that sera collected
during the first week after symptoms onset are better suited for
testing by CHIKV RT-PCR, rather than by CHIKV serological assays.
In addition, for subjects suspected of CHIKV infection who present
a negative CHIKV IgM result from an acute-phase sample, clinical
suspicion should not be discarded. Rather, a second serological test
should be performed on a convalescent-phase sample. We also
found that the Euroimmun IgM ELISA returned more equivocal
results and presented slightly lower specificity than that found for
the Inbios IgM ELISA, which may result in a higher rate of false-
positive cases if the Euroimunn test is applied in low chikungunya
prevalence scenarios.
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